Business Description
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
Business History
Price Overview
Last updated: Jun 27, 2026 8:57am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.72
Total Equity: $365.87M
Shares: 55,544,000
Total Debt: $51.62M
Cash: $286.50M
EBITDA: -$85.41M
Total Debt: $51.62M
Cash: $286.50M
Revenue: $308.05M
Shares: 55,544,000
Revenue: $308.05M
Revenue: $308.05M
Revenue: $308.05M
Total Equity: $365.87M
Tax Rate: -0.2%
Equity: $365.87M
Total Debt: $51.62M
Cash: $286.50M
Current Liabilities: $65.80M
Long-Term Debt: $51.62M
Total Debt: $51.62M
Total Equity: $365.87M
Shares: 55,544,000
Shares: 55,544,000
CapEx: -$9.36M
Shares: 55,544,000
Stock Price: $22.56
Net Income: -$95.57M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:37pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $34.5M | $75.0M | $136.2M | $224.5M | $308.1M |
| Cost of Revenue | $18.6M | $37.9M | $65.1M | $87.4M | $111.8M |
| Gross Profit | $15.9M | $37.1M | $71.0M | $137.1M | $196.2M |
| Operating Expenses | $70.0M | $117.8M | $180.2M | $233.7M | $300.1M |
| Operating Income | -$54.2M | -$80.7M | -$109.2M | -$96.6M | -$103.9M |
| Net Income | -$59.9M | -$87.2M | -$105.9M | -$91.4M | -$95.6M |
| EBITDA | -$50.7M | -$79.1M | -$98.1M | -$82.0M | -$85.4M |
| EPS | $-1.37 | $-1.96 | $-2.24 | $-1.75 | $-1.72 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:37pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $304.3M | $222.6M | $257.2M | $333.7M | $286.5M |
| Total Current Assets | $326.2M | $272.6M | $350.6M | $481.8M | $450.4M |
| Total Assets | $337.0M | $309.3M | $404.7M | $534.0M | $508.1M |
| Current Liabilities | $16.2M | $35.3M | $45.9M | $53.1M | $65.8M |
| Long-Term Debt | $50.0M | $51.2M | $51.3M | $51.5M | $51.6M |
| Total Liabilities | $69.9M | $112.3M | $124.0M | $131.8M | $142.2M |
| Total Equity | $267.1M | $197.1M | $280.8M | $402.2M | $365.9M |
| Retained Earnings | -$261.5M | -$348.7M | -$454.6M | -$546.0M | -$641.6M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:37pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$57.3M | -$80.4M | -$108.0M | -$99.2M | -$49.0M |
| Capital Expenditure | $-592,000 | -$2.7M | -$25.2M | -$4.4M | -$9.4M |
| Free Cash Flow | -$57.9M | -$83.0M | -$133.2M | -$103.6M | -$58.3M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $204.2M | -$79.4M | $34.6M | $76.5M | -$47.2M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:57am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$491.1M $484.6M – $499.2M
|
$586.0M $585.4M – $586.6M
|
$678.7M $666.8M – $688.8M
|
$794.9M $780.9M – $806.8M
|
| EBITDA |
$226.9M $223.8M – $230.6M
|
$270.7M $270.4M – $271.0M
|
$313.5M $308.0M – $318.2M
|
$367.2M $360.7M – $372.7M
|
| Net Income |
-$49.0M -$76.9M – -$35.0M
|
-$34.3M -$68.8M – -$19.8M
|
-$18.1M -$18.5M – -$17.7M
|
$35.5M $34.7M – $36.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:37pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +117.6% | +81.6% | +64.8% | +37.2% |
| Gross Profit Growth | +133.8% | +91.6% | +93.0% | +43.1% |
| Operating Income Growth | -49.0% | -35.2% | +11.5% | -7.5% |
| Net Income Growth | -45.6% | -21.5% | +13.7% | -4.5% |
| EBITDA Growth | -56.0% | -24.0% | +16.4% | -4.2% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-09 | Desai Antal Rohit | A-Award | 3,315.00 | $0.00 | $0 |
| 2026-06-09 | Desai Antal Rohit | A-Award | 5,853.00 | $28.78 | $168,449 |
| 2026-06-09 | Dodrill Amy M. | A-Award | 3,315.00 | $0.00 | $0 |
| 2026-06-09 | Dodrill Amy M. | A-Award | 5,853.00 | $28.78 | $168,449 |
| 2026-06-09 | Garrett Mary | A-Award | 3,315.00 | $0.00 | $0 |
| 2026-06-09 | Garrett Mary | A-Award | 5,853.00 | $28.78 | $168,449 |
| 2026-06-09 | Harris Taylor C. | A-Award | 3,315.00 | $0.00 | $0 |
| 2026-06-09 | Harris Taylor C. | A-Award | 5,853.00 | $28.78 | $168,449 |
| 2026-06-09 | Little Elisabeth Sandoval | A-Award | 3,315.00 | $0.00 | $0 |
| 2026-06-09 | Little Elisabeth Sandoval | A-Award | 5,853.00 | $28.78 | $168,449 |
| 2026-06-09 | MOLL FREDERIC H | A-Award | 3,315.00 | $0.00 | $0 |
| 2026-06-09 | MOLL FREDERIC H | A-Award | 5,853.00 | $28.78 | $168,449 |
| 2026-06-09 | PRESCOTT THOMAS M | A-Award | 3,315.00 | $0.00 | $0 |
| 2026-06-09 | PRESCOTT THOMAS M | A-Award | 5,853.00 | $28.78 | $168,449 |
| 2026-06-09 | PUCKETT DAN | A-Award | 3,315.00 | $0.00 | $0 |
| 2026-06-09 | PUCKETT DAN | A-Award | 5,853.00 | $28.78 | $168,449 |
| 2026-06-08 | Nouri Alaleh | S-Sale | 285.00 | $28.48 | $8,117 |
| 2026-06-08 | Waters Kevin | S-Sale | 357.00 | $28.48 | $10,167 |
| 2026-06-08 | Templin Barry L | S-Sale | 358.00 | $28.48 | $10,195 |
| 2026-04-16 | Templin Barry L | 0.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).